Table 3. Kaplan-Meier estimations of the efficacy as determined by on-treatment analysis applying different criteria for virological failure.
Virological efficacy | ||
---|---|---|
Virological failure definition | week 48 | week 96 |
HIV-RNA >200 copies/mL x2 or >200 x1 followed by loss to follow-up. | 95.6% (CI95, 94.5–96.7) | 91.5% (CI95, 89.6–93.4) |
HIV-RNA >50 copies/mL x2 or >50 x1 followed by loss to follow-up. | 94.4% (CI95, 93.1–97.7) | 85.2% (CI95, 82.9–87.5) |
HIV-RNA >50 copies/mL x2 or >50 x1 followed by loss to follow-up + treatment change due to a single detectable viremia. | 93.5% (CI95, 92.0–95.0) | 83.5% (CI95, 81.0–86.0) |